Iovance Biotherapeutics CEO Fardis departs following FDA setback for lead drug lifileucel

Iovance Biotherapeutics CEO Fardis departs following FDA setback for lead drug lifileucel

Source: 
Fierce Biotech
snippet: 

On the same day that Iovance Biotherapeutics disclosed that it received additional data requests on potency assays for its lead candidate lifileucel from the FDA, its chief executive Maria Fardis, Ph.D., told the company she'd be leaving.